Top

Published in:

01-04-2018 | Original Article

MRI assessment of erosion repair in patients with long-standing rheumatoid arthritis receiving double-filtration plasmapheresis in addition to leflunomide and methotrexate: a randomized controlled trial

Authors: Xiaoxia Yu, Lei Zhang, Lixin Wang, Weiwei Lu, Fengyan Sun, Ping Xu, Guobin Lan

Published in: Clinical Rheumatology | Issue 4/2018

Abstract

The objective of this study is to investigate whether the addition of double-filtration plasmapheresis (DFPP) to leflunomide and methotrexate repairs MRI bone erosion in patients with long-standing rheumatoid arthritis (RA). Seventy-two patients with highly active RA of > 3 years’ duration were randomized to receive DFPP in addition to DMARDs (leflunomide and methotrexate) or DMARDs. Contrast-enhanced MRI of the right wrist was performed at months 0, 6, and 12. MRI bone erosion, synovitis, and bone edema were scored with validated methods. The primary endpoint was the change in MRI bone erosion over 12 months. Patients treated with DFPP in addition to DMARDs demonstrated significantly greater decrease in MRI erosion score compared with those treated with DMARDs, being 11.3 ± 9.6 at month 12, compared with 16.9 ± 8.3 in patients with DMARDs (P < 0.001), and compared with 14.4 ± 9.6 at baseline (P < 0.001). 84.2% of patients treated with DFPP in addition to DMARDs demonstrated a decrease in MRI erosion score. Synovitis and bone edema improved significantly with DFPP in addition to DMARDs compared with DMARDs at months 6 and 12. (1.05 ± 1.7 and 2.0 ± 3.9 compared with 8.0 ± 1.4 and 12.6 ± 7.9 at month 12). Patients without synovitis and bone edema reached in 55.3% among patients with DFPP in addition to DMARDs. This study demonstrated that DFPP combination therapy significantly decreased bone erosion and received the primary goal of repair of erosions through abrogating MRI inflammation (synovitis and bone edema) in long-standing RA patients with high disease activity. The findings suggest that addition of DFPP is associated with repair of erosions and further suppression of inflammation.

Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola E, Montecucco C, Schoels M, van der Heijde D, T2T Expert Committee (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69(4):631–637. https://doi.org/10.1136/ard.2009.123919 CrossRefPubMedPubMedCentral

Cohen G, Gossec L, Dougados M, Cantagrel A, Goupille P, Daures JP, Rincheval N, Combe B (2007) Radiological damage in patients with rheumatoid arthritis on sustained remission. Ann Rheum Dis 66(3):358–363. https://doi.org/10.1136/ard.2006.057497 CrossRefPubMed

Molenaar ET, Voskuy AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BA (2004) Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 50(1):36–42. https://doi.org/10.1002/art.11481 CrossRefPubMed

Laganà B, Picchianti Diamanti A, Ferlito C, Germano V, Migliore A, Cremona A, Argento G, David V, Salemi S, D’Amelio R (2009) Imaging progression despite clinical remission in early rheumatoid arthritis patients after etanercept interruption. Int J Immunopathol Pharmacol 22(2):447–454. https://doi.org/10.1177/039463200902200221 CrossRefPubMed

van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Güler-Yüksel M, Zwinderman AH, Kerstens PJ, van der Lubbe PA, de Beus WM, Grillet BA, Ronday HK, Huizinga TW, Breedveld FC, Dijkmans BA, Allaart CF (2009) Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 68:914–921CrossRefPubMed

Forslind K, Svensson B (2016) MRI evidence of persistent joint inflammation and progressive joint damage despite clinical remission during treatment of early rheumatoid arthritis. Scand J Rheumatol 45(2):99–102. https://doi.org/10.3109/03009742.2015.1070902 CrossRefPubMed

Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K, Peterfy CG, Hensor E, Wakefield RJ, O'Connor PJ, Emery P (2008) An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 58(10):2958–2967. https://doi.org/10.1002/art.23945 CrossRefPubMed

Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, Wakefield RJ, O’Connor PJ, Emery P (2006) Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 54(12):3761–3773. https://doi.org/10.1002/art.22190 CrossRefPubMed

Sokolove J, Johnson DS, Lahey LJ, Wagner CA, Cheng D, Thiele GM, Michaud K, Sayles H, Reimold AM, Caplan L, Cannon GW, Kerr G, Mikuls TR, Robinson WH (2014) Rheumatoid factor as a potentiator of anti-citrullinated protein antibody mediated inflammation in rheumatoid arthritis. Arthritis Rheumatol 66(4):813–821. https://doi.org/10.1002/art.38307 CrossRefPubMedPubMedCentral

10.

Hecht C, Englbrecht M, Rech J, Schmidt S, Araujo E, Engelke K, Finzel S, Schett G (2015) Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA. Ann Rheum Dis 74(12):2151–2156. https://doi.org/10.1136/annrheumdis-2014-205428 CrossRefPubMed

11.

Humphreys JH, Verheul MK, Barton A, MacGregor AJ, Lunt M, Toes REM, Symmons DPM, Trouw LA, Verstappen SMM (2016) Anticarbamylated protein antibodies are associated with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk arthritis register. Ann Rheum Dis 75(6):1139–1144. https://doi.org/10.1136/annrheumdis-2015-207326 CrossRefPubMed

12.

Kastbom A, Strandberg G, Lindroos A, Skogh T (2004) Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 63(9):1085–1089. https://doi.org/10.1136/ard.2003.016808 CrossRefPubMedPubMedCentral

13.

Katchamart W, Koolvisoot A, Aromdee E, Chiowchanwesawakit P, Muengchan C (2015) Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis. Rheumatol Int 35(10):1693–1699. https://doi.org/10.1007/s00296-015-3271-8 CrossRefPubMed

14.

Bas S, Genevay S, Meyer O, Gabay C (2003) Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology 42(5):677–680. https://doi.org/10.1093/rheumatology/keg184 CrossRefPubMed

15.

Kastbom A, Forslind K, Ernestam S, Geborek P, Karlsson JA, Petersson IF, Saevarsdottir S, Klareskog L, van Vollenhoven RF, Lundberg K (2016) Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial. Ann Rheum Dis 75(2):356–361. https://doi.org/10.1136/annrheumdis-2014-205698 CrossRefPubMed

16.

Ismail N, Neyra R, Hakim RM(2001) Plasmapheresis. In: Daugirdas JT, Blake PG, Ing TS(ed) handbook of dialysis, 3rd edn. Lippincott Williams & Wilkins, Philadelphia, pp231–262

17.

Zhang Y-y, Zheng T, Chen D-m, Gong D-h, Ji D-x, Liu Z-h (2014) Comparison of double filtration plasmapheresis with immunoadsorption therapy in patients with anti-glomerular basement membrane nephritis. BMC Nephrol 315(128)

18.

Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324. https://doi.org/10.1002/art.1780310302 CrossRefPubMed

19.

Østergaard M, Peterfy C, Conaghan P, McQueen F, Bird P, Ejbjerg B, Shnier R, O'Connor P, Klarlund M, Emery P, Genant H, Lassere M, Edmonds J (2003) OMERACT rheumatoid arthritis magnetic resonance imaging studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. J Rheumatol 30(6):1385–1386PubMed

20.

Prevoo ML, van Gestel AM, van T Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. (1996)Remission in a prospective study of patients with rheumatoid arthritis: American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 35:1101–1105, 11

21.

Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V et al (1995) American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38(6):727–735. https://doi.org/10.1002/art.1780380602 CrossRefPubMed

22.

Felson DT, Anderson JJ, Lange ML, Wells G, LaValley MP (1998) Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 41(9):1564–1570. https://doi.org/10.1002/1529-0131(199809)41:9<1564::AID-ART6>3.0.CO;2-M CrossRefPubMed

23.

Haijun Zhang, Sizeng Zhang, Xing Lin, Ming Jiang (2004) Treatment of rheumatoid arthritis. In: Ming Jiang, DAVID Yu, Xiaoyi Lin (ed) Rheumatology, first edn. Huaxia, Beijing, pp771–827

24.

Peterfy C, Emery P, Tak PP, Østergaard M, DiCarlo J, Otsa K, Sarabia FN, Pavelka K, Bagnard M-A, Gylvin LH, Bernasconi C, Gabriele A (2016) MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study. Ann Rheum Dis 75(1):170–177. https://doi.org/10.1136/annrheumdis-2014-206015 CrossRefPubMed

25.

Axelsen MB, Eshed H-PK, Stengaard-Pedersen K, Hetland ML, Møller J, Junker P, Pødenphant J, Schlemmer A, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Dam MY, Hansen I, Horn HC, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun J, Krogh NS, Johansen JS, Østergaard M, OPERA study group (2015) A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial. Ann Rheum Dis 74(5):867–875. https://doi.org/10.1136/annrheumdis-2013-204537 CrossRefPubMed

26.

Conaghan PG, Peterfy C, Olech E, Kaine J, Ridley D, DiCarlo J, Friedman J, Devenport J, Troum O (2014) The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy. Ann Rheum Dis 73(5):810–816. https://doi.org/10.1136/annrheumdis-2013-204762 CrossRefPubMedPubMedCentral

27.

DUMMY

28.

Conaghan PG, Emery P, Østergaard M, Keystone EC, Genovese MC, Hsia EC, Xu W, Rahman MU (2011) Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial. Ann Rheum Dis 70(11):1968–1974. https://doi.org/10.1136/ard.2010.146068 CrossRefPubMedPubMedCentral

29.

Conaghan PG, Durez P, Alten RE, Burmester GR, Tak PP, Klareskog L, Catrina AI, DiCarlo J, Gaillez C, Le Bars M, Zhou X, Peterfy C (2013) Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Ann Rheum Dis 72(8):1287–1294. https://doi.org/10.1136/annrheumdis-2012-201611 CrossRefPubMed

30.

Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, Westhovens R, Luyten FP, Corluy L, Houssiau FA, Verschueren P (2007) Treatment of early rheumatoid arthritis. A randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. ARTHRITIS RHEUM 56(12):3919–3927. https://doi.org/10.1002/art.23055 CrossRefPubMed

31.

Boesen M, Boesen L, Jensen KE, Cimmino MA, Torp-Pedersen S, Terslev L, Koenig M, Danneskiold-Samsøe B, Røgind H, Bliddal H (2008) Clinical outcome and imaging changes after intraarticular (IA) application of etanercept or methylprednisolone in rheumatoid arthritis: magnetic resonance imaging and ultrasound-Doppler show no effect of IA injections in the wrist after 4 weeks. J Rheumatol 35(4):584–591PubMed

32.

Yu X, Wang L, Xu P, Lu W, Lan G, Ping L, Wang X, Tian J, Liu J (2012) Effects of double filtration plasmapheresis, leflunomide, and methotrexate on inflammatory changes found through magnetic resonance imaging in early rheumatoid arthritis. J Rheumatol 39(6):1171–1178. https://doi.org/10.3899/jrheum.110978 CrossRefPubMed

33.

Boeters DM, Nieuwenhuis WP, Verheul MK, Newsum EC, Reijnierse M, Toes REM, Trouw LA, van der Helm-van Mil AHM (2016) MRI-detected osteitis is not associated with the presence or level of ACPA alone, but with the combined presence of ACPA and RF. Arthritis Res Ther 18(1):179. https://doi.org/10.1186/s13075-016-1076-0 CrossRefPubMedPubMedCentral

34.

Li H, Song W, Li Y, Liu Y, Bai J, Li X, Mu F, Wang Y, Zhang F, Su L (2010) Diagnostic value of anti-cyclic citrullinated peptide antibodies in northern Chinese Han patients with rheumatoid arthritis and its correlation with disease activity. Clin Rheumatol 29(4):413–417. https://doi.org/10.1007/s10067-009-1337-2 CrossRefPubMed

35.

Tamai M, Kawakami A, Uetani M, Takao S, Tanaka F, Nakamura H, Iwanaga N, Izumi Y, Arima K, Aratake K, Kamachi M, Huang M, Origuchi T, Ida H, Aoyagi K, Eguchi K (2006) The presence of anti-cyclic citrullinated peptide antibody is associated with magnetic resonance imaging detection of bone marrow oedema in early stage rheumatoid arthritis. Ann Rheum Dis 65(1):133–134. https://doi.org/10.1136/ard.2005.04138 CrossRefPubMedPubMedCentral

36.

Ibn Yacoub Y, Amine B, Laatiris A, Hajjaj-Hassouni N (2012) Rheumatoid factor and antibodies against citrullinated peptides in Moroccan patients with rheumatoid arthritis: association with disease parameters and quality of life. Clin Rheumatol 31(2):329–334. https://doi.org/10.1007/s10067-011-1820-4 CrossRefPubMed

37.

Ajeganova S, van Steenbergen HW, Verheul MK, Forslind K, Hafström I, Toes RE, Huizinga TW, Svensson B, Trouw LA, van der Helm-van Mil AH (2017) The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor. Ann Rheum Dis 76(1):112–118. https://doi.org/10.1136/annrheumdis-2015-208870 CrossRefPubMed

38.

Yee A, Webb T, Seaman A, Infantino M, Meacci F, Manfredi M, Benucci M, Lakos G, Favalli E, Schioppo T, Meroni PL, Mahler M (2015) Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis. Immunol Res 61(1–2):24–30. https://doi.org/10.1007/s12026-014-8560-x CrossRefPubMed

39.

Smolen JS, Aletaha D, Mc Innes IB (2016) Rheumatoid arthritis. Lancet 388(10055):2023–2038. https://doi.org/10.1016/S0140-6736(16)30173-8 CrossRefPubMed

40.

Li L, Wen W, Jia R, Li Y, Liu X, Sun X, Li Z (2016) GITRL is associated with increased autoantibody production in patients with rheumatoid arthritis. Clin Rheumatol 35(9):2195–2202. https://doi.org/10.1007/s10067-016-3280-3 CrossRefPubMed

41.

Mateen S, Zafar A, Moin S, Khan AQ, Zubair S (2016) Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis. Clin Chim Acta 455:161–171. https://doi.org/10.1016/j.cca.2016.02.010 CrossRefPubMed

42.

Derksen VFAM, Huizinga TWJ, van der Woude D (2017) The role of autoantibodies in the pathophysiology of rheumatoid arthritis. Semin Immunopathol 39(4):437–446. https://doi.org/10.1007/s00281-017-0627-z CrossRefPubMedPubMedCentral

43.

Yu X, Ma J, Tian J, Jiang S, Xu P, Han H, Wang L (2007) A controlled study of double filtration plasmapheresis in the treatment of active rheumatoid arthritis. J Clin Rheumatol 13(4):193–198. https://doi.org/10.1097/RHU.0b013e318124a483 CrossRefPubMed

44.

Chen Y, Yang L, Li K, Liu Z, Gong D, Zhang H, Liu Z, Hu W (2016) Double filtration plasmapheresis in the treatment of antineutrophil cytoplasmic autoantibody associated vasculitis with severe renal failure: a preliminary study of 15 patients. Ther Apher Dial 20(2):183–188. https://doi.org/10.1111/1744-9987.12389 CrossRefPubMed

45.

Gong D, Ji D, Xu B, Liu Z (2013) More selective removal of myeloperoxidase-anti-neutrophil cytoplasmic antibody from the circulation of patients with vasculitides using a novel double-filtration plasmapheresis therapy. Ther Apher Dial 17(1):93–98. https://doi.org/10.1111/j.1744-9987.2012.01107.x CrossRefPubMed

Title: MRI assessment of erosion repair in patients with long-standing rheumatoid arthritis receiving double-filtration plasmapheresis in addition to leflunomide and methotrexate: a randomized controlled trial
Authors: Xiaoxia Yu
Lei Zhang
Lixin Wang
Weiwei Lu
Fengyan Sun
Ping Xu
Guobin Lan
Publication date: 01-04-2018
Publisher: Springer London
Published in: Clinical Rheumatology / Issue 4/2018
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-017-3956-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2018

Psoriatic arthritis: tissue-directed inflammation?

Vasodilator function worsens after cessation of tumour necrosis factor inhibitor therapy in patients with rheumatoid arthritis only if a flare occurs

Correction to: ADAM-17 is expressed in the inflammatory myopathy and is involved with interstitial lung disease

Adults with incident accelerated knee osteoarthritis are more likely to receive a knee replacement: data from the Osteoarthritis Initiative

Malnutrition and sarcopenia in a large cohort of patients with systemic sclerosis

Clinical characteristics of autoimmune rheumatic disease-related organizing pneumonia

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage